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Introduction
Macroautophagy (hereafter referred to as autophagy) and 
apoptosis represent the 2 processes through which altered or aged 
cells and organelles are removed. Autophagy involves sequestra-
tion of portions of the cytoplasm and intracellular organelles 
within autophagic vacuoles (named autophagosomes) that are 
sent to lysosomes for degradation.1 Apoptosis is the best-known 
form of programmed cell death and involves the activation of 
catabolic pathways that lead to the rapid destruction of cel-
lular organelles.2 Interestingly, the 2 processes are likely to be 
connected with each other in Alzheimer disease pathogenesis. 
Disruption of autophagy leads to amyloid-β (Aβ) peptide accu-
mulation in vacuoles and cell death.3,4 Aβ, in turn, has been 
shown to affect autophagy.5 Thus, it is plausible that Aβ plays 
a key role in linking the 2 processes with each other during AD.
Aβ is the central peptide in the amyloid hypothesis that has 
dominated the AD field for many years.6 Aß derives from amy-
loid precursor protein through BACE1 and γ-secretase process-
ing. Prior to its deposition in amyloid plaques, Aβ forms soluble 
oligomers that constitute the major killer form of the peptide.7 
Interestingly, concentrations of Aβ1-42 oligomers are higher in 
plasma of AD patients that control subjects (642.5 ng/ml vs. 
441.8 ng/ml). Furthermore they are negatively correlated with 
cognition while plasma levels of Aβ1-42 monomers do not differ 
between AD patients and controls (9.94 pg/ml vs. 8.42, respec-
tively).8 Monomers, instead, have been proposed to be involved 
in physiological processes. For instance, we recently identified a 
physiological function for monomeric Aβ1-42 that was able to 
trigger BACE1 transcription without affecting cell survival sug-
gesting that the boundary separating toxicity from a probable 
physiological signaling of Aβ is very narrow.9 However, oligomers 
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The role of autophagy and its relationship with apoptosis in Alzheimer disease (AD) pathogenesis is poorly under-
stood. Disruption of autophagy leads to buildup of incompletely digested substrates, amyloid-β (Aβ) peptide accumula-
tion in vacuoles and cell death. Aβ, in turn, has been found to affect autophagy. Thus, Aβ might be part of a loop in which 
it is both the substrate of altered autophagy and its cause. Given the relevance of different soluble forms of Aβ1-42 in AD, 
we have investigated whether monomers and oligomers of the peptide have a differential role in causing altered auto-
phagy and cell death. Using differentiated sK-n-Be neuroblastoma cells, we found that monomers hamper the formation 
of the autophagic BcL2-Becn1/Beclin 1 complex and activate the MAPK8/JnK1-MAPK9/JnK2 pathway phosphorylating 
BcL2. Monomers also inhibit apoptosis and allow autophagy with intracellular accumulation of autophagosomes and 
elevation of levels of Becn1 and Lc3-ii, resulting in an inhibition of substrate degradation due to an inhibitory action on 
lysosomal activity. Oligomers, in turn, favor the formation of the BcL2-Becn1 complex favoring apoptosis. in addition, 
they cause a less profound increase in Becn1 and Lc3-ii levels than monomers without affecting the autophagic flux. 
Thus, data presented in this work show a link for autophagy and apoptosis with monomers and oligomers, respectively. 
These studies are likely to help the design of novel disease modifying therapies.
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of Aβ1-42 are also likely to play a physiological role in synaptic 
plasticity and memory.10 Indeed, the membrane-affinity of oligo-
mers and monomers is very similar,11,12 with a higher propensity 
to attach to the membrane by the oligomers,13 and a lower affin-
ity to bind to the cell membrane by the monomers.14 There is the 
need to better differentiate the effects of the 2 Aβ species.
Defective autophagy has been implicated in AD.15 Autophagy 
initiation was found to be increased after Aβ stimulation16 and in 
an AD mouse model.3 Extensive autophagic-lysosomal pathology 
was found in the TgCRND8 mouse model of AD, an animal 
with an aggressive production of Aβ1-42.17 On the other hand, 
strong evidence indicates that Aβ is both produced and degraded 
during autophagy.3,4 In the healthy brain, autophagy may play 
a relatively minor role in basal Aβ production because efficient 
clearance of autophagic vacuoles (AVs) and lysosomal degrada-
tion of Aβ prevent its accumulation.18 However, in pathological 
conditions both endocytic and autophagic pathways are sites of 
APP processing and Aβ production.4 AVs are numerous in AD 
brains, particularly, in dystrophic neuritis.19 Autophagy is also 
evident in the perikarya of neurons with tangles. The accumu-
lation of immature AV forms in dystrophic neurites suggests 
that the transport and maturation of AVs to lysosomes may be 
affected in AD. Of note, AVs are a major reservoir of intracellular 
Aβ in the brain.3 Purified AVs contain full-length APP as well as 
β-secretase and the γ-secretase complex subunits PSEN1 (prese-
nilin 1) and NCSTN (nicastrin).
Additional evidence in favor of an involvement of autophagy 
in relationship to Aβ in AD derives from studies on the expres-
sion of a key regulator of the initiation of the autophagic process, 
BECN1. BECN1 levels are decreased in AD patients.20,21 The 
reduction of BECN1 is supposed to be caused by caspase-medi-
ated cleavage,22 another phenomenon involved in APP process-
ing and AD pathogenesis. CASP3 (caspase 3) processes GGA3 
(golgi-associated, gamma adaptin ear-containing, ARF binding 
protein 3),23 an adaptor protein involved in trafficking of BACE1 
to the lysosome for degradation. The GGA3-depletion induced 
by CASP3 affects the degradation of BACE1 and induces BACE1 
activity, determining an enhancement of Aβ peptide genera-
tion.23 Moreover, a selective increase of CASP3 has been found 
in the post-synaptic compartment of brains from early cases of 
AD.24 Autophagic markers ATG5, ATG12, and LC3 are also 
linked with plaques and tangles in AD.25 Morphological evi-
dence also shows that APP and Aβ peptides are colocalized with 
LC3-positive autophagosomes in a cell line overexpressing APP 
and in AD mouse models,3,26 suggesting that Aβ can be a sub-
strate of autophagy. Finally, it has been found that the accumula-
tion of insoluble Aβ1-42 and SQSTM1, a marker of autophagic 
flux, precedes the impairment of autophagic clearance and may 
be a cause of lysosomal failure.27 Together, these data support 
the model in which autophagy is crucial for the removal of Aβ 
peptides.
Collectively, these findings suggest that modulation of auto-
phagy may be a therapeutic target for diseases associated with 
protein aggregation. While autophagy clears certain aggregated 
proteins, upregulation of autophagy can also influence Aβ 
pathology, as autophagic vacuoles may represent a site of Aβ 
production and neurodegeneration. In this manuscript, given the 
relevance of soluble monomeric as well as oligomeric preparations 
of Aβ1-42 in AD pathogenesis, we studied their role in altering 
autophagy and causing cell death.
Results
Both Aβ1-42 monomers and oligomers impair autophagy
To determine whether Aβ1-42 oligomers and monomers 
affect autophagy, we measured levels of autophagy-associated 
proteins, BECN1, and LC3-II in differentiated SK-N-BE neu-
roblastoma cells treated with 1 µM Aβ1-42 oligomers and 
monomers. BECN1 participates in autophagosome formation. 
MAP1LC3/LC3 (microtubule-associated protein 1 light chain 
3) is a ubiquitin-like protein that becomes lipidated (LC3-II) 
and is tightly associated with the phagophore and autophago-
somal membranes.28 The distribution of these 2 proteins using 
a confocal scanning laser microscope is reported in Figure 1A. 
After 24 h both monomeric and oligomeric Aβ1-42 preparations 
increased BECN1 immunoreactivity; however a higher number 
of positive cells were observed after treatment with the mono-
meric preparation. LC3 A/B immunoreactivity was similar after 
24 h of incubation with Aβ1-42 monomers and oligomers. Then, 
to further study whether Aβ1-42 oligomers and monomers affect 
autophagy, we measured protein levels of BECN1 and LC3 by 
western blot (Fig. 1B). Both preparations were able to signifi-
cantly increase BECN1 levels, but the increase was more pro-
nounced with monomers than with oligomers (up to 3-fold with 
monomers vs. 2.5-fold with oligomers). Moreover, the increase 
was already present at 1 h of treatment, whereas it took about 8 h 
to start for oligomers. Examination of LC3-II levels also showed 
an increase in protein levels for both monomeric and oligomeric 
preparations. Monomers of Aβ1-42 produced a marked and sig-
nificant increase in LC3-I-II protein levels that started at 3 h 
and was still present after 48 h of treatment, whereas oligomers 
produced a transient increase that was no longer present after 8h 
to 12 h of incubation.
We also examined the effect of Aβ1-42 species on the auto-
phagic flux by assessing the levels of SQSTM1, one of the selective 
substrates of autophagy. SQSTM1 is a protein that is degraded by 
autophagy and starts lysosomal degradation linking ubiquitinated 
proteins to the autophagic machinery. Since SQSTM1 accumu-
lates when autophagy is inhibited, and decreases when autophagy 
is induced, SQSTM1 may be considered a marker of autophagic 
flux.29 The SQSTM1 protein levels after treatment with Aβ1-42 
monomers and oligomers are reported on Figure 2A. Cell treat-
ment with monomeric preparations produced a significant (> 
2-fold) increase in SQSTM1 levels after 1 h of incubation that 
lasted up to 24 h, whereas oligomers of Aβ1-42 caused a slight, 
but not significant decrease in SQSTM1 protein levels.
To determine whether Aβ1-42 monomeric or oligomeric 
preparations are able to affect the number of early and late 
autophagosomes, we used a RFP-GFP LC3 DNA construct. As 
expected, in Figure 2B, both treatments with monomers and 
oligomers induced a significant increase in the number of late 
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autophagosomes (GFP- RFP+ LC3-positive 
dots) suggesting that, at this time point, the 
autophagic flux is increased. More interest-
ingly, treatment of cells with monomers also 
strongly increased the number of early auto-
phagosomes (GFP+ RFP+ LC3-positive dots). 
Taken together these findings suggest that 
monomers and oligomers affect differently the 
autophagic flux and that monomers induced 
a too-strong increase in new autophagosomes 
that could be only partially degraded by the 
lysosomes.
Our next goal was to determine whether 
early autophagosomes are fused (the GFP- 
RFP+ LC3-positive dots are autophagosomes 
that have fused with the lysosomes) and 
digested by lysosomes. First we analyzed lyso-
somal formation. Figure 3A shows LAMP1 
(lysosomal-associated membrane protein 1) 
and Aβ1-42 immunostaining after 24 h of 
treatment with different Aβ species, suggest-
ing that lysosomal vesicles are formed and also 
that there is a colocalization with lysosomes 
and the 2 Aβ1-42 preparations. This finding 
does not necessarily mean that Aβ forms are 
transported (and also degraded) to lysosomes 
by autophagy because this process can also 
occur through endocytosis, chaperone-medi-
ated autophagy, or direct binding to lysosomal 
membrane or lysosomal membrane proteins.
Next, we measured lysosomal activity by 
evaluating CTSD/cathepsin D activity. We 
found that Aβ1-42 monomers, but not oligo-
mers, impair CTSD activity (~60% - 70%) 
after 6 h and up to 24 h of treatment (Fig. 3B). 
Pepstatin, a CTSD inhibitor, used as a posi-
tive control, induced a decrease (~85%) of 
the enzymatic activity after 8 h of incubation. 
Finally, we pretreated cells with the lysosomal 
inhibitor chloroquine at the concentration of 
100 µM for 24 h followed by exposure to the 
oligomeric preparation. Aβ1-42 was capable of 
mediating a strong and significant increase in 
LC3-II protein levels that was present at 3 h 
and lasted at least for 24 h (Fig. 3C), with a 
trend almost similar to monomers.
Aβ1-42 oligomers, but not monomers, 
induced necrotic and apoptotic cell death
Our next goal was to examine the necrotic 
cell death as LDH release in culture medium 
(Fig. 4A). The treatment of differentiated 
neuroblastoma cells with oligomeric Aβ1-
42 preparation induced a stronger (~60% 
vs. 20%) release of LDH compared with the 
monomeric form. Measurement of expres-
sion of cleaved CASP3, a critical executioner 
Figure 1. Treatment of differentiated sK-n-Be cells with 1 µM Aβ1-42 monomers and oligo-
mers significantly increase Becn1 and Lc3-i and Lc3-ii fluorescence intensity and protein lev-
els. (A) cells treated with 1 µM Aβ42 monomers and oligomers for 24 h were stained, after 
fixation and permeabilization, with Becn1 or Lc3 antibodies. After washing in PBs, sections 
were incubated with secondary antibodies raised in different species: 1:200 cyanine 3-con-
jugated donkey anti-mouse secondary antibody and 1:100 cyanine 2-conjugated anti-rabbit 
secondary antibody with 1% BsA in PBs. For counterstaining, cells were incubated for 3 min 
with DAPi diluted 1:50 in methanol 0.1 M and rinsed with PBs. After 24 h both monomeric 
and oligomeric Aβ1-42 preparations increased Becn1 immunoreactivity; however a higher 
number of positive cells were observed after treatment with the monomeric preparation. 
(B) Becn1 and Lc3-i/-ii protein levels in cells treated with 1 µM Aβ42 monomers and oligomers 
at different time points up to 48 h. Both preparations were able to significantly increase Becn1 
levels, but the increase was more pronounced with monomers than with oligomers (up to 
3-fold with monomers vs. 2.5-fold with oligomers). examination of Lc3-ii levels also showed an 
increase in protein levels for both monomeric and oligomeric preparations. Monomers of Aβ1-
42 led to a marked and significant increase in Lc3-ii protein levels that started at 3 h and was 
still present after 48 h of treatment, whereas oligomers produced a transient increase that was 
no longer present after 8 h to 12 h of incubation. The error bars represent standard deviations. 
experiments were conducted in triplicate. *, significantly different from controls (P < 0.05); **, 
significantly different from controls (P < 0.02).
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of apoptosis, through western blotting (WB) technique revealed 
that oligomeric Aβ1-42, but not the monomeric preparation, 
was capable of significantly increasing (2.5-fold) the cleavage of 
CASP3 at 3 and 6 h of incubation (Fig. 4B). Consistent with 
these results, immunocytochemistry of cleaved CASP3-positive 
neurons and terminal deoxynucleotidyltransferase-mediated 
biotinylated UTP Nick End Labeling and (TUNEL)-staining 
showed an increase in CASP3 cleavage and apoptotic nuclei at 
the same time points (Fig. 4C). Thus, differently from mono-
mers, oligomers are the only Aβ species that are likely to induce 
cell death.
The induction of apoptotic cell death mediated by oligo-
meric preparations of Aβ1-42 was corroborated by analysis of 
the CYCS release as well as the protein levels of the proapop-
totic effector BAK1 in the cytosol (Fig. 5A). Treatment with 
oligomeric Aβ1-42 increased the CYCS release (100 to 120%) 
Figure 2. Treatment of differentiated sK-n-Be cells with 1 µM Aβ1-42 monomers, but not oligomers, significantly decreased autophagic flux, through 
accumulation of early endosomes. (A) sQsTM1 protein levels in cells treated with 1 µM Aβ1-42 monomers and oligomers up to 48 h. Treatment of cells 
with monomeric preparations was followed by a significant (> 2-fold) increase in sQsTM1 levels after 1 h of incubation that lasted up to 24 h, whereas 
oligomers of Aβ1-42 caused a slight, but not significant decrease in sQsTM1 protein levels. (B) On the left, confocal images of representative cultured 
sK-n-Be neuronal cells transfected with GFP-rFP-Lc3 DnA for 24 h following 8 h of treatment with 1 µM Aβ1-42 monomers or oligomers. On the right, 
quantification of early and late autophagosomes per cells (15 cells) after treatment with 1 µM Aβ1-42 monomers and oligomers. The increase in number 
of early autophagosomes (GFP+-rFP+) was much higher in cells treated with monomeric preparation than in cells treated with oligomers, whereas late 
endosomes (GFP- rFP+) were significantly increased after treatment with both preparation. For counterstaining, cells were incubated for 3 min with 
DAPi diluted 1:50 in methanol 0.1 M and rinsed with PBs. experiments were conducted in triplicate. *, significantly different from controls (P < 0.05); **, 
significantly different from controls (P < 0.02).
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after 3 h and up to 24 h, and 
BAK1 protein levels (120 to 
150%) after 1 h and up to 24 
h (Fig. 5A). Data reported in 
Figure 5A indicate that the 
same experimental condi-
tions that induced an increase 
of BAK1 levels also produced 
a significant decrease of the 
antiapoptotic protein BCL2 
(B-cell CLL/lymphoma 2) 
(50%). As expected, treat-
ment of cells with monomeric 
preparations of Aβ1-42 did 
not affect these parameters 
(Fig. 5A).
To define the molecular 
mechanisms behind apop-
totic cell death, we analyzed 
the interaction between 
BCL2 and BECN1. It has 
been reported that BCL2 
interacts with BECN130 pro-
moting apoptosis,2 whereas 
its phosphorylation is likely 
to impede formation of the 
BCL2-BECN1 complex per-
mitting autophagy. Lysates 
from cells treated with both 
Aβ1-42 preparations, were 
immunoprecipitated with 
a polyclonal anti-BECN1 
antibody and blotted with 
BCL2 antibody. As shown in 
Figure 5B, we observed that 
only the treatment with Aβ1-
42 oligomers allowed the 
interaction between BCL2 
and BECN1, as demonstrated 
by the increase in BCL2 in 
samples immunoprecipitated 
with BECN1 after 3 and 6 
h of incubation. Thus, the 
formation of BCL2-BECN1 
complex may represent the 
mechanism through which 
oligomers promote apoptotic 
cell death.
Next, we studied lev-
els of cleaved CASP3 in 
SK-N-BE differentiated 
cells that overexpress BCL2 
to investigate whether the 
BCL2-BECN1 complex 
formation mediates apopto-
sis. As shown in Figure 5C, 
Figure 3. Treatment of differentiated sK-n-Be cells with 1 µM Aβ1-42 monomers affects autophagic flux through 
impairment of lysosomal activity. (A) Lysosomal-associated membrane protein 1 (LAMP1) immunostaining after 
24 h treatment with the Aβ species. cells treated with 1 µM Aβ42 monomers and oligomers for 24 h were stained, 
after fixation and permeabilization, with LAMP1 monoclonal and Aβ42 polyclonal antibodies. After washing in 
PBs, sections were incubated with secondary antibodies raised in different species: 1:200 cyanine 3-conjugated 
donkey anti-mouse secondary antibody and 1:100 cyanine 2-conjugated anti-rabbit secondary antibody) with 1% 
BsA in PBs. For counterstaining, cells were incubated for 3 min with DAPi diluted 1:50 in methanol 0.1 M and rinsed 
with PBs. As shown, lysosomal vesicles are formed and also there is a colocalization with lysosomes and the 2 Aβ1-
42 preparations. (B) cTsD activity evaluation in sK-n-Be differentiated cells after treatments with the 2 Aβ1-42 
preparations. Only treatment with Aβ1-42 monomers was followed by a significant decrease in the cTsD activity 
after 6 h and up to 24 h. Pepsatin, used as a positive control induced ~80% inhibition of the enzyme activity after 
8 h of incubation. (C) Lc3-ii protein levels in sK-n-Be cells pretreated with 100 µM chloroquine for 24 h and then 
treated with Aβ1-42 oligomeric preparation for 8 h. Pretreatment of cells with the lysosomal inhibitor was able of 
mediating a strong and significant increase in Lc3-ii protein levels, with a trend almost similar to monomers. The 
error bars represent standard deviations. experiments were conducted in triplicate. *, significantly different from 
controls (P < 0.05); **, significantly different from controls (P < 0.02).
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BCL2 protein levels were 
drastically increased in BCL2 
overexpressing cells compared 
with normal cells (+300%). 
Moreover, treatment with 1 
µM Aβ1-42 oligomers caused 
a significant decrease in BCL2 
levels in normal cells but not 
in overexpressing cells. Most 
importantly, BCL2 overex-
pression was able to attenuate 
the cleavage of CASP3 medi-
ated by oligomers, supporting 
the hypothesis that BCL2-
BECN1 complex formation 
mediates apoptosis.
Monomeric Aβ1-42, 
but not the oligomeric spe-
cies, causes activation of the 
M APK8/JNK1-M APK9/
JNK2 pathway with an 
increase in BCL2 phosphor-
ylation, as well as BACE1 
expression and activity
Given that in previous 
experiments we have demon-
strated that Aβ1-42 mono-
mers are able to activate the 
M A PK8 /JNK1-M A PK9 /
JNK2 pathway,31 the kinase 
that phosphorylates BCL232 
suppressing its complex 
with BECN1, we evaluated 
levels of nuclear phospho-
M A PK8 /JNK1-M A PK9 /
JNK2. Incubation of cells 
with Aβ1-42 monomeric 
preparation was followed 
by a robust activation of the 
M A PK8 /JNK1-M A PK9 /
JNK2 pathway, as shown by 
the significant increase (~3 to 
2.5-fold) in levels of phospho-
M A PK8 /JNK1-M A PK9 /
JNK2 in SK-N-BE nuclear 
fractions (Fig. 6A). In addi-
tion, measurement of BCL2 
phosphorylation by WB in 
cytosolic fractions of cells 
treated with Aβ1-42 mono-
mers revealed a significant 
increase (~2.5-fold) in BCL2 
phosphorylation, as expected 
with the activation of the 
M A PK8 /JNK1-M A PK9 /
JNK2 pathway (Fig. 6B). 
Figure 4. Treatment of differentiated sK-n-Be cells with 1 µM Aβ1-42 oligomers, but not monomers, significantly 
increases LDh release in the medium as well as cleavage of cAsP3 and DnA fragmentation. (A) LDh release in 
differentiated sK-n-Be treated with Aβ1-42 oligomers as well as monomers for 24 h. The treatment of differenti-
ated neuroblastoma cells with oligomeric Aβ1-42 preparation induced a more severe (~60% vs. 20%) release of 
LDh compared with the monomeric form. (B) cleaved-cAsP3 protein levels in cells treated with different Aβ 
species. We found that only oligomeric Aβ1-42, significantly increased (2.5-fold) the cleavage of cAsP3 at 3 h and 
6 h of incubation. (C) cells treated with both oligomers and monomers of Aβ1-42 for 6 h were fixed, permeabi-
lized, and stained with polyclonal antibodies against cleaved cAsP3 (red) or with the DnA fragmentation stain 
TUneL (green), and then analyzed by confocal microscopy. Monomers did not change cell number compared 
with controls, whereas oligomers strongly decreased it (oligomers: 61% increase in apoptotic nuclei vs. control; 
monomers: 18% increase in apoptotic nuclei vs. controls). Arrows indicate puncta of either cleaved cAsP3 or 
TUneL staining. higher magnification views of given areas are encapsulated in squares. The nuclear stain DAPi 
(4,6 diamidino-2phenylindole, blue) was used to stain cells. scale bars: 100 µm, or 15 µm for higher magnification 
views. The error bars represent standard deviations. experiments were conducted in triplicate. *, significantly dif-
ferent from controls (P < 0.05); **, significantly different from controls (P < 0.02).
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Thus, destruction of the BCL2-BECN1 complex mediated by 
activation of the MAPK8/JNK1-MAPK9/JNK2 pathway by 
Aβ1-42 monomers may represent the mechanism that cells use 
to promote autophagy instead of apoptosis under treatment with 
Aβ1-42 oligomers.
We previously demonstrated that monomers of Aβ1-42 
augment BACE1 gene transcription through this MAPK8/
JNK1-MAPK9/JNK2 signaling pathway activation.31 We there-
fore confirmed that MAPK8/JNK1-MAPK9/JNK2 activation 
precedes a significant increase in BACE1 mRNA, as well as its 
protein levels and activity. As shown in Figure 6, Aβ1-42 mono-
mers caused a 1.5- to 2.5-fold increase in BACE1 mRNA at 1 
h to 6 h of incubation (Fig. 6C), BACE1 protein levels (~2 to 
3-fold) starting at 3 h and still present at 48 h (Fig. 6D), and 
Figure 5. Treatment of differentiated sK-n-Be cells with 1 µM Aβ1-42 oligomers significantly increases cYcs and BAK1 and decreases BcL2 levels and 
allows the interaction between BcL2 with Becn1. (A) cYcs, BAK1 and BcL2 protein levels in differentiated sK-n-Be cells treated with Aβ1-42 oligomers 
as well as monomers up to 24 h. Treatment with oligomeric Aβ1-42 increased the cYcs release (100 - 120%) after 3 h and up to 24 h, and BAK1 protein 
levels (120–150%) after 1 h and up to 24 h, whereas BcL2 levels resulted significantly decreased (50%). Treatment of cells with monomeric preparations of 
Aβ1-42 did not affect these parameters. (B) cells treated with Aβ preparations were immunoprecipitated with polyclonal Becn1 antibody and revealed 
with monoclonal BcL2 antibody. We found that BcL2 is linked to Becn1 only after 3 h to 6 h of treatment with Aβ1-42 oligomers. (C) BcL2 and cleaved 
cAsP3 protein levels in differentiated sK-n-Be control and overexpressing BcL2 cells treated with 1 µM Aβ1-42 oligomers. BcL2 overexpression was able 
to attenuate the cleavage of cAsP3 mediated by oligomers. The error bars represent standard deviations. experiments were conducted in triplicate. **, 
significantly different from controls (P < 0.02).
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BACE1 activity (~50%) starting at 12 h and still present at 48 h 
(Fig. 6E).
Next, we asked whether Aβ1-42 oligomers are capable of acti-
vating the MAPK8/JNK1-MAPK9/JNK2 pathway. Exposure 
of differentiated neuroblastoma cells to oligomeric preparations 
did not modify the nuclear translocation of phospho-MAPK8/
J N K 1 - M A P K 9 / J N K 2 
(Fig. 7A). Furthermore, 
oligomers did not induce a 
significant increase in BACE1 
mRNA levels (Fig. 7B), as 
well as protein levels (Fig. 7C) 
and activity (Fig. 7D). Taken 
all together, these findings 
demonstrate that mono-
meric Aβ1-42, but not the 
oligomeric species, causes 
M A PK8 /JNK1-M A PK9 /
JNK2 pathway activation.
In order to exclude that 
differences in mass between 
monomers and oligomers or 
in rate and/or proportion 
of monomers and oligomers 
entering cells, produce appar-
ent differences between the 2 
Aβ species, we treated cells 
with both oligomeric and 
monomeric Aβ1-42 at differ-
ent concentrations (100 nM, 
200 nM, 1 µM, 5 µM) for 
6 h. As shown in Figure 8, 
we observed that monomers 
were not capable of increasing 
CASP3 levels even at higher 
concentrations, whereas 
they increased BACE1 pro-
tein levels (2.5–3.5-fold 
increase) at any concentra-
tion. Oligomers, in turn, 
failed to increase BACE1 
levels at any concentration, 
but significantly increased 
cleaved CASP3 protein levels 
at all concentrations. Taken 
together, these findings sug-
gest that our results were 
not due to differences in the 
amount of oligomers and 
monomers reaching the cells 
as a consequence of differ-
ences in mass between mono-
mers and oligomers, as well as 
rate or proportion of mono-
mers and oligomers entering 
cells.
The presence of BECN1 is crucial for the toxicity mediated 
by Aβ1-42 oligomers
To confirm that the mechanism underlying the toxicity 
exerted by Aβ1-42 oligomers may be mediated by BECN1-BCL2 
interaction, we studied some parameters of toxicity in SK-N-BE 
differentiated cells stably silenced for BECN1. As shown in 
Figure  6. Treatment of differentiated sK-n-Be cells with 1 µM Aβ1-42 monomers increases BAce1 expression 
and activity through the activation of the MAPK/JnK pathway. (A) nuclear pMAPK/JnK protein levels in differ-
entiated sK-n-Be treated with Aβ1-42 monomers up to 24 h. The treatment was followed by a robust activation 
of the MAPK/JnK pathway, as shown by the significant increase (~3 to 2.5-fold) in levels of phospho- MAPK/JnK 
in nuclear fractions. (B) Phosphorylated BcL2 protein levels of in cytosolic fractions of cells treated with mono-
mers up to 8 h. As expected with the activation of the MAPK/JnK pathway, cells treated with Aβ1-42 monomers 
revealed a significant increase (~2.5-fold) in BcL2 phosphorylation (C–E) BAce1 expression, protein levels, and 
activity in cells treated with Aβ1-42 monomeric preparation. Treatment of cells with Aβ1-42 monomers induced 
a 1.5- to 2.5-fold increase in BACE1 mrnA, as well as a 100% to 200% increase in BAce1 protein levels and a 35% 
increase in BAce1 activity. The error bars represent standard deviations. experiments were conducted in tripli-
cate. *, significantly different from controls (P < 0.05); **, significantly different from controls (P < 0.02).
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Figure 9A, silenced cells did 
not display a band for BECN1 
protein. Furthermore, silencing 
BECN1 completely protected the 
decrease of BCL2 and the cleav-
age of CASP3 (Fig. 9A), demon-
strating that BECN1 is necessary 
for oligomeric Aβ1-42-induced 
toxicity.
Evaluation of the LDH release 
in culture medium of control and 
BECN1 silenced neuroblastoma 
cells treated with Aβ1-42 oligo-
mers showed no LDH release 
after 12 h and 24 h of incubation 
following silencing of BECN1 
compared with a 50% release in 
control cells (Fig. 9B).
Finally, we studied if BECN1 
silencing changes autophagic 
flux. As shown in Figure 9C, 
the absence of BECN1 lowered 
the basal levels of both LC3 and 
SQSTM1 and treatment of cells 
with the oligomeric preparation 
of Aβ1-42 did not modify this 
trend.
Primary cortical neuronal 
cultures treated with Aβ1-42 
monomers and oligomers con-
firm findings from SK-N-BE 
neuroblastoma cell lines on 
autophagy and apoptosis
To enhance the significance 
of our findings obtained on 
a neuroblastoma cell line, we 
investigated the effects of Aβ1-
42 monomers and oligomers on 
autophagy and apoptosis, using mouse primary cortical neuro-
nal cultures. We treated cells with 1 µM Aβ1-42 monomers or 
oligomers for 6, 8, 12, 24, and 48 h. As shown in Figure 10A, 
monomers induced a significant increase in LC3-II protein 
levels that was present at 6 h and at the following time point 
including 48 h. Treatment of neuronal cells with oligomers 
produced, in turn, a transient increase of LC3-I-II protein lev-
els including the 6 h and the 12 h time points, but not the 
24 h and 48 h time points. When we assessed CTSD activity 
we observed that Aβ1-42 monomers decreased CTSD activity 
by about 40% to 60%, whereas oligomeric Aβ1-42 did not 
(Fig. 10B). Finally, we found that monomers, but not oligo-
mers, increased BACE1 activity of approximately 30% after 
12 to 48 h of treatment (Fig. 10C). On the other hand, oligo-
mers, but not monomers, induced apoptotic cell death as con-
firmed by the significant decrease (-50%) of BCL2 levels after 
3 and 6 h of treatment and the increase (+100 to 150%) of 
cleaved CASP3 protein levels (Fig. 10D). Taken all together, 
Figure  7. Treatment of differentiated sK-n-Be cells with 1 µM Aβ1-42 oligomers does not affect BAce1 
expression and the JnK pathway. (A) nuclear pJnK protein levels in differentiated sK-n-Be treated with Aβ1-
42 oligomers up to 24 h. Aβ1-42 oligomers do not activate JnK phosphorylation in nuclear fraction of dif-
ferentiated sK-n-Be cells. (B–D) BAce1 expression, protein levels, and activity in cells treated with Aβ1-42 
oligomeric preparation. Treatment of cells with Aβ1-42 oligomers was not followed by significant induction 
of BAce1 mrnA, protein levels, and activity. The error bars represent standard deviations. experiments were 
conducted in triplicate.
these findings extend to the primary culture preparation find-
ings from the neuroblastoma cell line on the involvement of 
Aβ1-42 monomers and oligomers in autophagy and apoptosis, 
respectively.
Discussion
We have found that Aβ1-42 monomers and oligomers have 
different effects on autophagy and cytototoxicity. Monomers 
hamper the formation of the BCL2-BECN1 complex activating 
the JNK pathway that phosphorylates BCL2, as well as inhib-
iting apoptosis and allowing autophagy. Monomers also cause 
intracellular accumulation of autophagosomes with elevation of 
levels of BECN1 and LC3-II, resulting in inhibition of substrate 
degradation due to reduction of lysosomal activity. Oligomers, 
in turn, facilitate the production of the BCL2-BECN1 com-
plex favoring apoptosis. In addition, they cause a less profound 
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increase in BECN1 and LC3-II levels with no effect on the auto-
phagic flux (Fig. 11).
Little is known on the relationship between autophagy and 
apoptosis. This relationship is multifaceted in the sense that 
autophagy might represent a stress adaptation that suppresses 
apoptosis, avoiding cell death, whereas in other cellular set-
tings, autophagy represents an alternative mechanism to cellu-
lar damage that is called autophagic cell death (or type II cell 
death). Autophagy induction may have a general inhibitory effect 
beyond protein aggregate removal. For instance, pretreatment of 
cells with rapamycin (an autophagy inducer) decreases the mito-
chondrial mass by ~50% and reduces the susceptibility of cells to 
mitochondrial outer membrane permeabilization, one of the cru-
cial steps that mediate apoptotic cell death.33 In this system, inhi-
bition of autophagy mediated by depletion of ATG7 suppressed 
the protective effect of rapamycin in vitro, in human cells.33 On 
the other hand, mouse embryonic fibroblasts (MEFs) derived 
from double-knockout bax–/– bak1–/– mice when treated with the 
topoisomerase-2 inhibitor, etoposide, an agent capable of dam-
aging DNA, do not undergo apoptosis and show massive auto-
phagy. BAX and BAK1 are 2 members of the BCL2 family, that 
are required for mitochondrial 
outer membrane permeabiliza-
tion and thus for apoptotic cell 
death.34 In other cellular set-
tings, other types of damages in 
the apoptotic machinery, such 
as caspase inhibition, induce 
cell death mediated by auto-
phagy. Treatment of selected 
cell types (such as the L929 
mouse fibrosarcoma and the 
human Jurkat T cell lymphoma) 
with Z-VAD-FMK, an inhibitor 
of cysteine proteases, can induce 
autophagic cell death.35
Through our work, we 
gathered a more complete 
understanding of the interplay 
between the 2 processes in AD 
pathogenesis in relationship 
to the elevation of different 
soluble Aβ species. We have 
demonstrated that oligomers 
lead to apoptosis favoring the 
formation of the BCL2-BECN1 
complex. Consistent with this 
finding, compelling evidence 
demonstrates that the regulation 
of BCL2-BECN1 interaction 
represents a central mechanism 
by which autophagy is turned 
off in response to different cel-
lular stimuli.36 BECN1 interac-
tion with BCL2 and BCL2L1 
would lead to protection against 
autophagy. On the contrary, the disruption of the BCL2-BECN1 
complex may be a mechanism through which cells promote auto-
phagy during different stress conditions.37,38 Thus, in some cir-
cumstances, such as nutrient deprivation or hypoxia, it has been 
reported that inhibition of autophagy is followed by an acceler-
ated cell death with the presence of hallmarks of apoptosis, such 
as chromatin condensation and caspase-activation.
The mechanisms through which autophagy inhibition may 
facilitate cell death are not completely clear. It is possible that 
autophagy inhibition results in a bioenergetic deficiency that 
mediates apoptosis.39 Thus, the deficiency in redox equivalents 
favors oxidative reactions, probably through a direct effect on 
mitochondria that triggers apoptosis.40 This is in agreement with 
our previous results showing that Aβ1-42 oligomers, but not 
monomers, increase oxidative stress.41
We found that suppression of BECN1 leads to a protection 
of apoptotic cell death mediated by Aβ1-42 oligomers. This 
finding is in apparent contrast with the demonstration that 
activation of autophagy or overexpression of BECN1 can pre-
vent neuronal cell death and promote clearance of toxic protein 
aggregates.16 Furthermore, it has been reported that reduced 
Figure  8. Treatment of differentiated sK-n-Be cells with different concentrations of Aβ1-42 monomers or 
oligomers does not modify the effects observed with the 1 µM concentratiob. BAce1 and cAsP3 protein lev-
els in differentiated sK-n-Be cells treated with a range (100 nM–5 µM) of Aβ1-42 monomers or oligomers for 
6 h. We observed that monomers are not capable of increasing cAsP3 levels even at higher concentrations, 
whereas they increase BAce1 protein levels at any concentration. Oligomers, in turn, fail to increase BAce1 
levels at any concentration, but significantly increase cleaved cAsP3 protein levels at all concentrations. The 
error bars represent standard deviations. experiments were conducted in triplicate. *, significantly different 
from controls (P < 0.05); **, significantly different from controls (P < 0.02).
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expression of BECN1 in 
AD brains is associated 
with an increase in Aβ lev-
els and with a derangement 
of autophagosome degrada-
tion.42 One hypothesis is 
that in absence of BECN1 
the apoptosis is turned off 
with activation of a BECN 
independent autophagic 
machinery and consequent 
overproduction of Aβ 
mediated by BACE1 over-
expression. These appar-
ently conflicting findings 
would require further 
investigation.
On the other hand, 
Aβ1-42 monomers lead 
to autophagy and ham-
per the formation of the 
BCL2-BECN1 complex 
by activating the MAPK8/
J N K 1- M A P K 9 / J N K 2 
pathway that phosphory-
lates BCL2.32 This path-
way is connected with all 
the pathological hallmarks 
of AD. MAPK8/JNK1-
MAPK9/JNK2 activation 
modulates the phosphory-
lation of APP, leading 
to regulation of Aβ lev-
els,43 as well as to MAPT/
tau phosphorylation in 
vitro.44 Furthermore, the 
MAPK8/JNK1-MAPK9/
JNK2 pathway is activated 
in preclinical models of 
AD, including Tg2576 and 
Tg2576/PS1P264 L trans-
genic mice,45,46 as well as 
in brains of AD patients.47 
Indeed, we have previously 
detected a significant acti-
vation of MAPK8/JNK1-
MAPK9/JNK2-AP1 in 
oxidative stress in vitro as 
well as in vivo models, as a 
pathway that mediates the 
upregulation of BACE1.48
Data obtained in the present work have confirmed our pre-
vious results showing that Aβ1-42 monomers are capable of 
upregulating BACE1 expression by interfering with its lysosomal 
degradation leading to an amyloid vicious cycle.49 We recently 
found that Aβ1-42 monomers, but not oligomers (data not 
Figure 9. Becn1 is needed for the toxicity mediated by Aβ1-42 oligomers. (A) Becn1, BcL2, and cleaved cAsP3 pro-
tein levels in sK-n-Be cell lines stably expressing a specific shrnA against BECN1 or scrambled shrnA treated with 
Aβ1-42 oligomers up to 6 h. Becn1 is observed only in cells expressing scrambled shrnA while a band correspond-
ing to the protein is not observed in cell expressing shrnA against BECN1. BcL2 protein levels remain unchanged in 
cells silenced for Becn1 treated with Aβ1-42 oligomers up to 6 h, whereas cleaved cAsP3 are protected but slightly 
significant with respect to untreated cells. (B) LDh release in culture medium in control as well as in silenced neuro-
blastoma cells treated with Aβ1-42 oligomers for 24 h. in silenced cells oligomers failed to induce necrotic cell death 
after 12 h and 24 h of treatment. (C) Lc3-ii and sQsTM1 protein levels in cells with and without silencing for Becn1 
and treated with oligomers of Aβ1-42 for 8 h and 12 h. The absence of Becn1 lowered the basal levels of both Lc3 
and sQsTM1 and treatment of cells with the oligomeric preparation of Aβ1-42 did not modify this trend. The error 
bars represent standard deviations. experiments were conducted in triplicate. *, significantly different from controls 
(P < 0.05); **, significantly different from controls (P < 0.02).
shown), downregulate the activity of UCHL1 (ubiquitin car-
boxyl-terminal esterase L1 [ubiquitin thiolesterase]), through the 
activation of total NFKB pathway. The decrease in UCHL1 activ-
ity interferes with the lysosomal machinery as demonstrated by 
the decrease in CTSD activity and the accumulation of BACE1 
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in lysosomes after treatment with Aβ1-42 monomers as well as 
with an UCHL1 inhibitor. The mechanism through which this 
enzyme impairs lysosomes needs further investigations.
Alterations in the endosome-lysosome machinery have also 
been previously reported in AD.50 BACE1 and Aβ are enriched 
in autophagic vacuoles in APP transgenic mouse models.17 
Furthermore, autophagic vacuoles accrue in dystrophic neurites 
in AD brains.19
Our manuscript shows a link for autophagy and apoptosis 
with monomers and oligomers, respectively. This is important in 
light of the fact that the exact role of monomers and oligomers 
in AD remains to be clearly defined. The higher neurotoxicity 
exerted by oligomers with respect to monomers suggests that this 
event can be mediated by production of reactive oxygen species41 
or other mediators and is able to kill neurons to induce apoptosis. 
On the other hand, monomers, being less cytotoxic, preferentially 
induce toxicity by modulating APP 
processing, increasing BACE1 expres-
sion and activity and thus resulting in 
a further accumulation of Aβ. Thus, 
our data suggest that both Aβ species 
are relevant to AD pathogenesis. Most 
importantly, these studies will help 
designing novel therapies that will cure the disease or at least 
alleviate its symptoms.
Materials and Methods
Cell culture differentiation and treatments
SK-N-BE neuroblastoma cells were maintained in RPMI 
(Roswell Park Memorial Institute) 1640 medium (Sigma-Aldrich, 
R8758) containing 2 mM glutamine (Sigma-Aldrich, G7513) 
and supplemented with 10% fetal bovine serum (Sigma-Aldrich, 
F7425), 1% nonessential amino acids (Sigma-Aldrich, R7131), 
and 1% antibiotic mixture (penicillin-streptomycin-amphoteri-
cin (Sigma Aldrich A5955) in a humidified incubator at 37 °C 
with 5% CO
2
. For differentiation, 2 × 106 cells were plated in 
75-cm2 culture flasks (Costar, 430651) and treated with 10 µM 
Figure 10. Primary cortical neuronal cul-
tures treated with 1 µM Aβ1-42 mono-
mers and oligomers confirm findings 
from sK-n-Be neuroblastoma cell lines 
on autophagy and apoptosis. (A) Lc3 i-ii 
protein levels in cells treated with Aβ1-42 
monomers and oligomers at different 
time points. Monomeric preparations 
induce a significant increase in Lc3-ii 
protein levels that started at 1 h and was 
still observed after 48 h of incubation. 
Treatment of neuronal cells with oligo-
meric preparation produced a transient 
increase of Lc3-ii protein levels that was 
present after 6 h and 12 h, but not 24 h 
and 48 h. (B) cTsD activity in cortical 
cultures treated with Aβ1-42 monomers 
and oligomers up to 48 h. Only Aβ1-42 
monomers significantly decreased cTsD 
activity about 40% to 60% between 6 
and 48 h. (C) BAce1 activity in cortical 
cultures treated with Aβ1-42 mono-
mers and oligomers. Monomers, but 
not oligomers, increase BAce1 activity 
of approximately 40% after 12 h to 48 
h of treatment. (D) BcL2 and cleaved 
cAsP3 protein levels in primary corti-
cal cultures treated with Aβ1-42 mono-
mers and oligomers. Oligomers, but not 
monomers, induce apoptotic cell death 
as confirmed by the significant decrease 
(-50%) of BcL2 and increase (+100 to 
150%) of cleaved cAsP3 protein levels. 
The error bars represent standard devia-
tions. experiments were conducted in 
triplicate. *, significantly different from 
controls (P < 0.05); **, significantly differ-
ent from controls (P < 0.02).
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retinoic acid (Sigma-Aldrich, R2625) for 10 d. Cells were incu-
bated with 0.1–5 µM Aβ1-42 peptides (Anaspec, 24224) up to 
48 h. The lyophilized synthetic peptides were dissolved as a stock 
solution in 1,1,1,3,3,3-hexafluoro-2-propanol (Sigma-Aldrich, 
105228) and stored at −80 °C in aliquots. Monomeric prepara-
tions, after evaporation of propanol, were brought to 1 µM (final 
concentration) with sterile double distilled water, centrifuged at 
10000 g for 10 min to avoid aggregation and immediately added 
to the cell culture.49 Oligomeric preparations were maintained 
at 4 °C for 24 h and then added to the cells.41,51,52 The quality of 
these Aß preparations was routinely controlled using WB and by 
transmission electron microscopy.
The lysosomal inhibitor chloroquine (Sigma-Aldrich, C6628) 
was used at the concentration of 100 µM for 24 h.
Cell extracts
Whole-cell extracts were prepared in ice-cold lysing buffer [1 
ml of phosphate-buffered saline (PBS; Sigma-Aldrich, P4417) 
was mixed with 1% Triton X-100 (Fluka, 93418); 10 µl 10% 
SDS (Sigma-Aldrich, L4509); 5 µl 1 M dithiothreitol (Sigma-
Aldrich, D9163); 6 µl 0.1% phenylmethylsulfonylfluoride 
(Sigma-Aldrich, P7626), 1% aprotinin (Sigma-Aldrich, A6279)] 
for 120 min. The lysates were cleared by centrifugation at 14000 
g for 25 min. Cytosolic and nuclear fractions were obtained as 
previously described.53
Primary cortical neuronal cultures
Primary neuronal cultures were prepared from the cortices of 
P0 pups of C57 mice. Culture plates were coated with 15 µg/
mL poly-L-ornithine (Sigma-Aldrich, 3655) for 45 min at room 
temperature. Poly-L-ornithine was then removed and wells were 
soaked with 4 µg/mL mouse laminin (Gibco, 23017-015) for 12h 
to 16 h in a cell culture incubator at 37 °C, 95% humidity and 
5% CO
2
. Forebrains were dissected in ice cold HBSS (Gibco, 
14175-053) with 0.5% w/v D-glucose (Sigma-Aldrich, G8270) 
and 25 mM HEPES (Gibco, 15360-056), under a dissection 
microscope (Leica, Zoom 2000, MOF-1045). Dissociation was 
performed in ice-cold dissection medium plus 0.01% w/v Papain 
Figure 11. Proposed effects on autophagy and apoptosis elicited by Aβ1-42 monomers and oligomers. (A) Monomers impede formation of the BcL2-
Becn1 complex by activation of the MAPK/JnK pathway that phosphorylates BcL2. Monomers also cause early endosome accumulation due to an inhibi-
tory action on lysosomal activity, resulting in intracellular accumulation of autophagosomes with elevation of levels of Becn1 and Lc3-ii, and inhibition 
of substrate degradation. (B) Oligomers favor the formation of the BcL2-Becn1 complex leading to apoptosis. They also cause a less profound increase 
in Becn1 and Lc3-ii levels and do not affect the autophagic flux.
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(Worthington Biochemical Corporation, LS003126), 0.1% 
w/v dispase (Roche, 04 942 078 001) and 0.01% w/v DNase 
(Worthington Biochemical Corporation, DR1), first by means 
of sterile razor blades, then by serial pipetting with flamed sterile 
glass Pasteur pipettes, and incubation at 37 °C twice for 15 min. 
Cells were then spun down at 220 g for 5 min at 4 °C, resus-
pended in Neurobasal Medium (Gibco, 21103-049) with 2% B27 
(Gibco, 17504-044), 1 mM Na Pyruvate (Gibco, 11360-088), 
100 units/ml penicillin-streptomycin solution (Gibco, 15070-
063), 2 mM Glutamax (Gibco, 35050-038), filtered through a 
40-µm cell strainer, counted and plated on coated 6-well plates 
at a density of about 400,000 cells/well. Culture medium was 
completely replaced after 16 h to 20 h, and new medium (30% 
of starting volume) was added every 3 d until needed. After 15 d 
cells were treated with 1 µM Aβ 1-42 monomers or oligomers.
Antibodies and immunoblot analysis
The following antibodies were used: polyclonal anti-BECN1 
(dilution 1:800; Abcam, ab62472); polyclonal anti LC3 (dilution 
1:800; Sigma-Aldrich, L8918) and monoclonal anti-ACTB/β 
actin (dilution 1:1000; Sigma-Aldrich, A3854); polyclonal anti-
CASP3 (dilution 1:1000; Cell Signaling Technology, 9665S) 
and polyclonal anti-pMAPK8/9 (JNK1/2, dilution 1:1000; Cell 
Signaling Technology, 4668S); polyclonal anti-MAPK/JNK 
(dilution 1:200; BD PharMingen Sparks, 610628), monoclonal 
anti CYCS (dilution 1:250; BD PharMingen Sparks, 556432); 
polyclonal anti-BAK1 (dilution 1:200; Millipore, 04-433); 
monoclonal anti-BCL2 (dilution 1:200; Millipore, 05-729); 
polyclonal anti-pBCL2 (dilution 1:250; Millipore, 05-843R); 
polyclonal anti-BACE1 (dilution 1:400; Millipore, 195111); anti-
SQSTM1 (dilution 1:2000, Sigma-Aldrich, P0067). Cell lysates 
and nuclear fraction were separated on 9.3% sodium dodecyl sul-
fate-polyacrylamide gels (Sigma-Aldrich, 01708), using a mini-
PROTEAN II electrophoresis cell (Bio-Rad, 165-3301).
Proteins were transferred onto nitrocellulose membranes 
(GE-Healthcare, RPN203D). Nonspecific binding was blocked 
with 50 g/l nonfat dry milk in 50 mM TRIS-HCl, pH 7.4, 
containing 200 mM NaCl and 0.5 mM Tween-20. The blots 
were incubated with different primary antibodies, followed by 
incubation with peroxidase-conjugated anti-mouse (Bio-Rad, 
170-6516) or anti-rabbit (Bio-Rad, 170-6515) immunoglobulins 
in Tris-buffered saline Tween [150 mM sodium chloride solu-
tion (Sigma-Aldrich, S6546) 10 mM TRIS-HCl pH 7.4 (Sigma 
Aldrich, T5941) 0.05% Tween 20 (Sigma-Aldrich, P1379)] 
containing 20 g/l nonfat dry milk. Reactions were developed 
with an enhanced chemiluminescence system according to the 
manufacturer’s protocol (Bio-Rad, 170-5061). In some experi-
ments, lysates were immunoprecipitated with the polyclonal anti-
body to BECN1 (Abcam, 62472) and conjugated with protein 
A Sepharose beads (Sigma-Aldrich, P6649) for 12 h at 4 °C. 
Immunoprecipitated proteins were separated in 9.3% gels and 
detected with BCL2 antibody.
Confocal immunofluorescence
For immunofluorescence experiments, cells were plated in 
12-well plates (BD Biosciences, 351143), at a concentration of 
40,000 cells/cm2. Cultured cells were fixed with 4% buffered 
paraformaldehyde for 15 min at room temperature. Samples were 
washed 3 times with PBS. In order to permeabilize cells, samples 
were incubated for 10 min in PBS containing 0.3% Triton X-100 
(PBST) followed by a washout with PBS. After blocking nonspe-
cific binding sites with 1% BSA Sigma-Aldrich, A7906) in PBST, 
cells were incubated at 4 °C overnight with the following pri-
mary polyclonal antibodies: i) polyclonal anti-BECN1 antibody 
(1:200; Abcam, 62472), ii) polyclonal anti-LC3A/B antibody 
(anti-microtubule-associated protein 1 light chain 3, isoforms α 
and β, 1:200; Novus Biologicals Inc., NB100-2331), iii) mono-
clonal anti-LAMP1 antibody 1:200; Calbiochem, AB2971), iv) 
polyclonal Aβ1-42 (1:500; Sigma-Aldrich, A2101), v) poyclonal 
anti-cleaved-CASP3 antibody (1:400; Cell Signaling Technology 
Inc., 9665S). After washing in PBS, sections were incubated with 
secondary antibodies raised in different species: 1:200 cyanine 
3-conjugated donkey anti-mouse secondary antibody (1:200; 
Jackson Research Laboratories, 715-165-151) and cyanine 
2-conjugated anti-rabbit secondary antibody (1:100; Jackson 
ImmunoResearch Laboratories, 711-5461-52) with 1% BSA in 
PBS. For counterstaining, cells were incubated for 3 min with 
4′,6-diamidino-2-phenylindole (DAPI; Sigma, D9564) diluted 
1:50 in methanol 0.1 M and rinsed with PBS. Finally, coverslips 
were mounted with a drop of 1:1 phosphate buffer-glycerol solu-
tion. The samples were examined with a Leica TCS SP5 confocal 
laser scanning microscope (Leica, CLSM).
TUNEL staining
Cell apoptosis was assessed through The DeadEndTM 
Fluorometric TUNEL System (Promega, Madison, WI, USA) 
following the manufacturer’s instructions. DAPI was employed 
to stain nuclei.
LDH release
The activity of the lactate dehydrogenase was determined 
using a commercially available kit (Sigma-Aldrich, TOX7) 
according to the manufacturer’s protocol. The assay is based on 
the reduction of NAD by LDH. The resulting reduced NAD 
(NADH) is utilized in the stoichiometric conversion of a tet-
razolium dye. The resulting colored compound was measured 
spectrophotometrically. The amount of LDH activity in cell-free 
aliquots of culture medium was used as an indicator of relative 
cell viability as well as a function of membrane integrity. Values 
for control and treated cells were expressed as a percentage of the 
LDH released by cells lysed with Triton X-100.
Gene expression analysis
Primer sequences, designed with PRIMER 3 software 
(Applied Biosystems, 4361938) were:
Human BACE1:
5′-CATTGGAGGT ATCGACCACT CGCT-3′
5′CCACAGTCTT CCATGTCCAA GGTG-3′.
Human ACTB:
5′-GGCACTCTTC CAGCCTTCCT TC-3′
5′-GCGGATGTCC ACGTCACACT TCA-3′
Quantitative PCR was performed on a real-time iCycler 
sequence detector instrument (Bio-Rad, iCycler iQTM Real-Time 
PCR Detection System). After 3 min of initial denaturation, 
the amplification profile included 30 s denaturation at 95 °C 
and extension at 72 °C. Primer annealing was performed for 
30 s at 60 °C. The results were obtained with the comparative Ct 
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method using the arithmetic Equation 2-ΔΔCt. Samples obtained 
from at least 3 independent experiments were used to calculate 
the mean and SD.
For the quantitative SYBR Green (2× iQ YBR Green PCR 
Super Mix; Bio-Rad, 170-8882) real-time PCR, 40 ng of cDNA 
was used per reaction. RNA extraction was performed with the 
RNeasy kit, according to the manufacturer’s protocol, for cell lines 
(Qiagen, 956034), cDNA was obtained with the SuperScript® III 
Cells Direct cDNA Synthesis Kit (Invitrogen, 18080200).
BACE1 activity
The activity of BACE1 was determined using a commercially 
available secretase kit from Calbiochem (565785) according to the 
manufacturer’s protocol. Cells were lysed in cold 1× Extraction 
Buffer (ready for use in the kit) to yield a final protein concentra-
tion of 1 mg/ml. The method is based on the secretase-dependent 
cleavage of a secretase-specific peptide conjugated to the fluores-
cent reporter molecules EDANS and DABCYL, which results 
in the release of a fluorescent signal that can be detected on a 
fluorescence microplate reader (VICTOR Multilabeled Counter, 
Perkin Elmer, 1420-018) (excitation wavelength of 355 nm and 
emission 510 nm). The level of secretase enzymatic activity is 
proportional to the fluorimetric reaction. Data were expressed as 
percentage change over activity level of control cells.
CTSD activity assay
The CTSD activity assay kit (Abcam, ab65302) is a fluo-
rescence-based assay that utilizes the preferred CTSD substrate 
sequence GKPILFFRLK(Dnp)-DR-NH2 labeled with MCA. 
Cell lysates that contain CTSD cleave the synthetic substrate to 
release fluorescence, which can be easily quantified using a fluo-
rescence plate reader (VICTOR Multilabeled Counter, Perkin 
Elmer, 1420- 018) at Ex/Em = 328/460.
mRFP-GFP-LC3 plasmid transfection
Cells were transfected with the tandem mRFP-GFP-LC3-
expressing plasmid ptfLC3 (Addgene, 21074) using 
Lipofectamine 2000 (Invitrogen, 11688-019) according to the 
manufacturer’s instructions.
Lentiviral vectors and virus production
Recombinant lentiviruses delivering anti-BECN1 shRNA 
specific for human BECN1 (TRCN0000033552 for BECN1, 
GenBankTM NM_003766) from the TRC library (the RNAi con-
sortium) in pLKO lentiviral vectors were used (Openbiosystems, 
Thermo Scientific). The generation of BCL2-encoding lenti-
virus was achieved by using a SIN-PGK-hBCL2-WHV vector 
as described previously.54 A pLKO vector containing scrambled 
shRNA (Openbiosystems, Thermo Scientific) in BECN1 knock-
down experiments or a SIN-PGK-WHV empty vector in BCL2 
upregulation experiments were used as control vectors. Self-
inactivating lentiviral vectors were produced by cotransfecting 
293T cells with the lentivirus expression plasmid and packaging 
plasmids using the calcium phosphate method. Infectious lenti-
viruses were harvested at 48 h post-transfection, the supernatant 
was collected, filtered, concentrated by ultracentrifugation, re-
suspended in 1% BSA in PBS, and then stored at −80 °C until 
use as previously described.55 Viral particle content was assayed 
for the p24 core antigen by using the p24 antigen enzyme-linked 
immunosorbent assay (RETROtek, 22-157-319) according to the 
manufacturer’s instructions.
Generation of stable knockdown cell lines
To establish SK-N-BE cell lines stably expressing a spe-
cific shRNA against BECN1 or overexpressing BCL2, 2–5 × 
106 SK-N-BE cells were seeded in T25 cell culture flasks and 
transduced with 50 ng of p24/ml culture medium. In parallel, 
SK-N-BE cells were transduced with a lentiviral vector encod-
ing a scrambled shRNA (shRNAsc Openbiosystems, Thermo 
Scientific) or a SIN-PGK-WHV empty vector) as an infection 
control. After 48 h, the transduced cells were trypsinized, and 
selection was initiated by diluting the cells 10-fold and adding 
10 µg/ml puromycin (Sigma-Aldrich, P9620).
Statistical analysis
Data in bar graphs represent mean ± SD, and were obtained 
from average data of at least 3 independent experiments. 
Morphological images are representative of at least 3 experiments 
with similar results. Statistical analysis was performed by the 
Student t test or ANOVA, followed by the Bonferroni post-hoc 
test, when appropriate (P < 0.05 was considered significant).
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